AI Meets Biotech The High Stakes IPO of Generate Biomedicines
The biggest question surrounding the IPO of Generate Biomedicines is whether artificial intelligence can truly change how drugs are created—or if investors are getting ahead of reality. This isn’t just another biotech listing. It’s a test of whether AI can deliver real outcomes in one of the most complex and capital-intensive industries in the world.
Read More